Your browser doesn't support javascript.
loading
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
Fisher, Benjamin A; Veenith, Tonny; Slade, Daniel; Gaskell, Charlotte; Rowland, Matthew; Whitehouse, Tony; Scriven, James; Parekh, Dhruv; Balasubramaniam, Madhu S; Cooke, Graham; Morley, Nick; Gabriel, Zoe; Wise, Matthew P; Porter, Joanna; McShane, Helen; Ho, Ling-Pei; Newsome, Philip N; Rowe, Anna; Sharpe, Rowena; Thickett, David R; Bion, Julian; Gates, Simon; Richards, Duncan; Kearns, Pamela.
Afiliação
  • Fisher BA; Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; National Institute for Hea
  • Veenith T; Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Department of Critical Care Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Slade D; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Gaskell C; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Rowland M; Kadoorie Centre for Critical Care Research, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • Whitehouse T; Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Department of Critical Care Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Scriven J; Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK; Department of Infectious Diseases, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Parekh D; Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Department of Critical Care Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Department of Respiratory Medicine
  • Balasubramaniam MS; Department of Critical Care Medicine, Royal Bolton Hospital, Bolton, UK.
  • Cooke G; Department of Infectious Disease, Imperial College London, London, UK.
  • Morley N; Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK.
  • Gabriel Z; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Wise MP; Department of Critical Care Medicine, University Hospital of Wales, Cardiff, UK.
  • Porter J; Department of Respiratory Medicine, University College Hospital, London, UK.
  • McShane H; Jenner Institute, University of Oxford, Oxford, UK.
  • Ho LP; Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Newsome PN; Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Rowe A; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Sharpe R; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Thickett DR; Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Department of Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Bion J; Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Department of Critical Care Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Gates S; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Richards D; Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK.
  • Kearns P; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Lancet Respir Med ; 10(3): 255-266, 2022 03.
Article em En | MEDLINE | ID: mdl-34922649
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Humans Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article País de publicação: Reino Unido